Serological cross-reactivity using a SARS-CoV-2 ELISA test in acute Zika virus infection, Colombia
Objectives: We investigated seroreactivity by using a commercial SARS-CoV-2 ELISA test in samples collected from different groups of individuals, including patients diagnosed to have Dengue, Zika, and Chikungunya infection between 2015 and 2019, from an endemic area in the Caribbean Colombian region. Methods: A total of 127 sera samples obtained from six different groups of individuals were included in this study: Group A: patients with confirmed SARS-CoV-2 infection; Group B: patients with symptoms suggestive of COVID-19 or asymptomatic contacts with confirmed patients; Group C: patients with acute or recent dengue virus infection; Group D: patients with acute Zika virus infection; Group E: patients with previous Chikungunya virus infection; and Group F: individuals with exposure to spotted fever group rickettsiae. Results: Overall, group A, group B, and group D showed seroreactivity to SARS-CoV-2 in 92%, 75%, and 26% of samples, respectively; furthermore, group C, group E, and group F showed 100% seronegativity. Conclusions: We found 26% of serological cross-reactivity in patients with acute Zika virus infection by using a commercial SARS-CoV-2 ELISA test. Further studies are needed to evaluate whether serological cross-reaction is maintained with time in nonacute patients with previous exposure to the Zika virus and its effect in SARS-CoV-2 serosurveys in endemic areas for this arbovirus..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:101 |
|---|---|
| Enthalten in: |
International Journal of Infectious Diseases - 101(2020), Seite 191-193 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Álvaro A. Faccini-Martínez [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Arbovirus infection |
|---|
| doi: |
10.1016/j.ijid.2020.09.1451 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ071997628 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ071997628 | ||
| 003 | DE-627 | ||
| 005 | 20230309104348.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2020.09.1451 |2 doi | |
| 035 | |a (DE-627)DOAJ071997628 | ||
| 035 | |a (DE-599)DOAJc886aeb6b0ef464dabbb91ff278457b0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a Álvaro A. Faccini-Martínez |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serological cross-reactivity using a SARS-CoV-2 ELISA test in acute Zika virus infection, Colombia |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objectives: We investigated seroreactivity by using a commercial SARS-CoV-2 ELISA test in samples collected from different groups of individuals, including patients diagnosed to have Dengue, Zika, and Chikungunya infection between 2015 and 2019, from an endemic area in the Caribbean Colombian region. Methods: A total of 127 sera samples obtained from six different groups of individuals were included in this study: Group A: patients with confirmed SARS-CoV-2 infection; Group B: patients with symptoms suggestive of COVID-19 or asymptomatic contacts with confirmed patients; Group C: patients with acute or recent dengue virus infection; Group D: patients with acute Zika virus infection; Group E: patients with previous Chikungunya virus infection; and Group F: individuals with exposure to spotted fever group rickettsiae. Results: Overall, group A, group B, and group D showed seroreactivity to SARS-CoV-2 in 92%, 75%, and 26% of samples, respectively; furthermore, group C, group E, and group F showed 100% seronegativity. Conclusions: We found 26% of serological cross-reactivity in patients with acute Zika virus infection by using a commercial SARS-CoV-2 ELISA test. Further studies are needed to evaluate whether serological cross-reaction is maintained with time in nonacute patients with previous exposure to the Zika virus and its effect in SARS-CoV-2 serosurveys in endemic areas for this arbovirus. | ||
| 650 | 4 | |a Diagnosis | |
| 650 | 4 | |a Endemic diseases | |
| 650 | 4 | |a Arbovirus infection | |
| 650 | 4 | |a Validation study | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 700 | 0 | |a Ricardo Rivero |e verfasserin |4 aut | |
| 700 | 0 | |a Evelin Garay |e verfasserin |4 aut | |
| 700 | 0 | |a Alejandra García |e verfasserin |4 aut | |
| 700 | 0 | |a Salim Mattar |e verfasserin |4 aut | |
| 700 | 0 | |a Yesica Botero |e verfasserin |4 aut | |
| 700 | 0 | |a Ketty Galeano |e verfasserin |4 aut | |
| 700 | 0 | |a Jorge Miranda |e verfasserin |4 aut | |
| 700 | 0 | |a Caty Martínez |e verfasserin |4 aut | |
| 700 | 0 | |a Camilo Guzmán |e verfasserin |4 aut | |
| 700 | 0 | |a Germán Arrieta |e verfasserin |4 aut | |
| 700 | 0 | |a Hector Contreras |e verfasserin |4 aut | |
| 700 | 0 | |a Hugo Kerguelen |e verfasserin |4 aut | |
| 700 | 0 | |a Maria Moscote |e verfasserin |4 aut | |
| 700 | 0 | |a Eimi Brango |e verfasserin |4 aut | |
| 700 | 0 | |a Veronica Contreras |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Infectious Diseases |d Elsevier, 2015 |g 101(2020), Seite 191-193 |w (DE-627)DOAJ000043923 |x 18783511 |7 nnns |
| 773 | 1 | 8 | |g volume:101 |g year:2020 |g pages:191-193 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijid.2020.09.1451 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/c886aeb6b0ef464dabbb91ff278457b0 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1201971220321676 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1201-9712 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 101 |j 2020 |h 191-193 | ||